Month: February 2014

Study Suprachoroidal shunt with topical travoprost reduces IOP

WASHINGTON — Early study findings suggest that implantation of a suprachoroidal stent significantly reduces IOP and medication burden in phakic patients with open-angle glaucoma, according to a presenter here. In this study of the suprachoroidal shunt implantation with travoprost, there were substantial reductions in pressure, with all eyes achieving a pressure of 18 mm Hg or lower at 1 and 2 years, and most eyes achieving 15 mm Hg at 1 and 2 years,” Jonathan S. Myers, MD, said at the American Glaucoma Society meeting.

Speaker: Cataract surgery, goniosynechialysis together increase IOP control in angle closure glaucoma

WASHINGTON — Cataract removal and goniosynechialysis work together to lower IOP in patients with angle closure glaucoma and significant synechiae, possibly avoiding further surgery, a speaker said here. Even though phacoemulsification alone may result in significant widening of the anterior chamber angle, combining goniosynechialysis with the cataract surgery could achieve better IOP control while also avoiding a trabeculectomy, Marlene R. Moster, MD, told colleagues at the American Glaucoma Society meeting.

BLOG: #BobCostasPinkeye

Admit it. You were more than a little bit interested in poor Bob Costas and his pink eye. Heck, if you were anything like me, it’s all your non-eye doc friends wanted to talk to you about. Maybe you even tweeted about it with a fancy hashtag. Guilty on that one, personally. But more than any of that, weren’t you fascinated by not only the whole spectacle (pun intended), but also about how and why it got to be such a big deal?

FDA, AGS workshop yields consensus recommendations

WASHINGTON — Panels of glaucoma specialists concurred here that only 1 year of follow-up is needed to assess safety endpoints in studies of minimally invasive glaucoma surgery devices. “The overwhelming majority of complications are going to occur promptly, so yes, I think a year is enough,” panelist George L. Spaeth, MD, said, agreeing with all other panelists at the joint workshop of the American Glaucoma Society and the U.S. Food and Drug Administration convened to advance the science of MIGS device implantation. The FDA is “listening carefully,” Malvina B. Eydelman, (Read more...)

Allergan reports 14.6% growth in net product sales for fourth quarter

Allergan reported $1.66 billion in total product net sales for the fourth quarter, which constitutes a 14.6% increase over total product net sales for the corresponding quarter in 2012, according to a press release. Total specialty pharmaceuticals net sales increased 14% compared with the fourth quarter of 2012, and total core medical devices net sales increased 17% over the prior year’s fourth-quarter numbers. Allergan also reported $1.04 in diluted earnings per share attributable to stockholders, which is less than the $1.05 in diluted earnings per share attributable to stockholders reported (Read more...)